The thyroid conversion problem: why normal TSH misses 30% of patients

By Rohan Smith · Functional & Nutritional Medicine, Adelaide · Published May 11, 2026

What TSH actually measures — and what it doesn’t

TSH (thyroid-stimulating hormone) is a pituitary hormone. The pituitary releases it in response to circulating thyroid hormone levels through a negative feedback loop — when free T4 drops, TSH rises to drive the thyroid to produce more. When T4 is sufficient, TSH falls. As a screening test for overt primary hypothyroidism, where the thyroid gland itself is failing to produce enough hormone, TSH is sensitive and clinically useful.^[1]

The limitation: TSH only reflects what is happening upstream of T4 production. It tells you whether the gland is being pushed to produce hormone. It does not tell you whether the T4 that gets produced is being converted to active T3 at the tissue level, whether T3 is reaching receptors, or whether reverse T3 is competitively blocking those receptors. All three of those steps happen downstream of TSH and can fail without TSH ever moving outside the lab reference range.^[2]

This is the gap that conversion problems live in. A patient can have a perfectly normal TSH while running on insufficient cellular thyroid hormone — and the standard test will miss it every time it is run in isolation.

The deiodinase enzymes — and why Selenium and Zinc matter

Three deiodinase enzymes regulate thyroid hormone activity in tissue: DIO1, DIO2, and DIO3. DIO1 is most active in the liver and kidneys and converts T4 to T3 for systemic circulation. DIO2 operates inside the brain, pituitary, and brown adipose tissue, converting T4 to T3 locally for cellular use. DIO3 does the opposite — it inactivates T4 by converting it to reverse T3, and inactivates T3 by converting it to T2.^[3]

All three deiodinases are selenoproteins. They contain selenocysteine at their active site and cannot function without adequate selenium. Selenium deficiency directly impairs T4 to T3 conversion and increases reverse T3.^[4] South Australian soils are relatively low in selenium, and dietary intake in Australia sits at the lower end of recommended ranges for many adults — particularly those avoiding seafood or following plant-dominant diets.

Zinc is required for the conversion of T4 to T3 and for the binding of T3 to its nuclear receptor. Studies in zinc-deficient subjects show reduced T3 levels alongside normal or elevated TSH, with restoration of T3 following zinc repletion.^[5] Iron and iodine are similarly relevant, though their roles sit slightly upstream — affecting hormone production rather than peripheral conversion specifically.

The practical point: deiodinase function is dependent on micronutrient status. Persistent suboptimal levels of selenium and zinc — common in busy modern eating patterns — quietly degrade peripheral T3 availability without registering on TSH testing.

Cortisol and the Reverse T3 shunt

Sustained physiological stress is one of the most consistent drivers of conversion failure. When cortisol stays elevated — through chronic psychological stress, inflammatory illness, surgical recovery, sustained caloric restriction, or sleep deprivation — DIO3 activity increases. T4 is preferentially shunted toward reverse T3 instead of being converted to active T3.^[6]

This pattern has a name in the endocrinology literature: non-thyroidal illness syndrome (also called euthyroid sick syndrome or low T3 syndrome). It is well-documented in critical care, post-surgical recovery, and chronic illness populations. What is less appreciated is how often it presents in ambulatory patients with sustained stress loads, persistent post-viral fatigue, or restrictive dieting histories.^[7]

Reverse T3 is metabolically inactive but it is not benign. It binds T3 receptors competitively, which means tissue-level thyroid hormone signalling can be impaired even when free T3 is in range. The clinical picture is a slowed metabolism, low body temperature, cold extremities, brain fog, and weight gain — alongside a TSH the GP correctly reports as normal.^[8]

Caloric restriction below 1,200–1,400 calories per day for sustained periods reliably triggers this shunt in healthy adults. It is one reason why stubborn weight loss plateaus after months of dieting often coincide with new-onset fatigue, hair loss, and cold intolerance — the body has down-regulated metabolism through reduced T3 conversion. The hormones and stress page covers the broader HPA axis pattern that drives this.

Gut and liver — where conversion actually happens

The liver is the largest single site of T4 to T3 conversion in healthy adults, accounting for roughly 60% of peripheral T3 production. Hepatic conversion can be impaired by non-alcoholic fatty liver disease, chronic alcohol intake, sluggish phase I and phase II detoxification, and metabolic syndrome — all increasingly common in a busy adult population.^[9]

The gut microbiome contributes approximately 20% of T3 conversion through bacterial sulfatase enzymes that deconjugate thyroid hormone metabolites. Dysbiosis — characterised by reduced bacterial diversity, loss of beneficial species, and overgrowth of opportunistic organisms — reduces this contribution. The result is lower circulating T3 even when T4 production and TSH are unchanged.^[10]

This is one mechanism by which patients with chronic gut conditions — SIBO, IBS, post-antibiotic dysbiosis — develop subclinical hypothyroid symptoms without any thyroid pathology of their own. The thyroid is fine. The conversion environment isn’t. The gut health page covers how dysbiosis is assessed and addressed in clinical practice.

Why Hashimoto’s makes conversion harder

Hashimoto’s thyroiditis is the most common cause of hypothyroidism in iodine-replete countries, including Australia. The autoimmune destruction of thyroid tissue gradually reduces T4 production over years to decades, with TSH rising to compensate as the gland fails. Standard treatment is levothyroxine (T4) replacement, titrated to keep TSH in range.

The problem: the same immune and inflammatory drivers that produce TPO antibodies also impair peripheral conversion. Hashimoto’s patients commonly have elevated inflammatory cytokines (IL-6, TNF-alpha) that reduce DIO1 and DIO2 activity, alongside higher rates of selenium deficiency and gut dysbiosis.^[11] The clinical result is the well-known Hashimoto’s presentation: TSH on target, T4 in range, but symptoms persist — cold intolerance, weight gain, fatigue, brain fog, hair thinning, depressed mood.

Selenium repletion has been studied repeatedly in Hashimoto’s. Multiple trials show reductions in TPO antibody levels with selenium supplementation over six to twelve months, and patient-reported symptom improvements that track with antibody decline.^[12][13] The mechanism is plausible: selenium repletes deiodinase function, reduces oxidative stress on the thyroid, and modulates the inflammatory response. This is the kind of intervention that requires testing first — selenium supplementation without baseline status testing carries its own risks at higher doses.

For Hashimoto’s patients managed on levothyroxine alone who continue to have symptoms despite an ‘optimal’ TSH, the conversion question is the next clinically meaningful step. The thyroid and metabolism page covers how this is approached in clinical assessment.

When conversion is the missing piece

The clinical pattern that points to conversion failure is consistent: TSH within reference range (often 1.5–3.5 mIU/L), free T4 in the lower-normal range, free T3 at the lower edge or below range, and reverse T3 elevated. Symptoms match hypothyroidism — cold intolerance, weight gain or weight-loss resistance, persistent fatigue not improved by sleep, hair thinning, dry skin, brain fog, depressed mood, slow recovery from exercise. TPO antibodies may or may not be elevated.

What changes with this finding is the treatment direction. If the bottleneck is conversion rather than T4 production, simply prescribing more T4 often fails to resolve symptoms — and in some patients can worsen them, because a struggling conversion system has even more T4 to shunt toward reverse T3. The clinical work shifts to identifying what is driving the conversion failure: nutrient repletion (selenium, zinc, iron, iodine where indicated), HPA axis support, gut function, and inflammation reduction.^[14]

The pace of recovery typically tracks with the duration of the underlying drivers. Conversion patterns that have been running for six months often improve within three months of targeted intervention. Patterns running for years — particularly in patients with long-standing Hashimoto’s, sustained stress histories, or chronic gut conditions — usually take six to twelve months to fully reverse. The chronic fatigue and burnout page covers how overlapping presentations are assessed.

Frequently Asked Questions

Is reverse T3 testing worth doing?

It is when symptoms persist despite a normal TSH, particularly when there is a history of sustained stress, restrictive dieting, chronic illness, or post-viral fatigue. Reverse T3 is most clinically useful interpreted alongside free T3 — the ratio of free T3 to reverse T3 reveals more than either marker in isolation. As a stand-alone test it is less informative.

Can conversion be fixed with diet and lifestyle alone?

Often yes — depending on the driver. If the bottleneck is selenium and zinc deficiency, repletion through diet and targeted supplementation typically restores conversion within three to six months. If the driver is sustained cortisol from chronic stress, the conversion improvement tracks with HPA axis recovery, which takes longer. If gut dysbiosis or hepatic dysfunction is involved, those need to be addressed first. Diet and lifestyle are usually the foundation, with targeted clinical support for the harder cases.

Does this mean my GP got it wrong?

No. TSH-only testing is a reasonable first-line screen and catches most overt hypothyroidism. The standard panel is designed to detect gland-level failure. What it isn’t designed to detect is peripheral conversion failure — that requires a wider panel and a different question. A functional medicine workup adds layers to the standard assessment rather than replacing it.

How long does it take to address conversion failure?

Most patients see meaningful symptom improvement within three months when nutrient drivers are the primary issue. Patterns rooted in long-standing HPA axis dysregulation, autoimmune Hashimoto’s, or chronic gut conditions typically take six to twelve months to fully resolve. The pace tracks with how long the underlying drivers have been running.

Is this different from being on T3 medication?

Yes — and they aren’t mutually exclusive. T3 medication (or combination T4/T3 therapy) is sometimes appropriate when conversion remains impaired despite addressing the upstream drivers, or when a patient has known DIO2 polymorphisms that reduce conversion at the genetic level.^[15] The functional approach starts by identifying and treating what is driving the conversion failure. Where conversion can be restored without exogenous T3, that is usually the more sustainable path.

Ready to find answers?

If your TSH has been called normal but you don’t feel normal — cold, tired, foggy, plateaued — a full thyroid workup is usually the first step that moves things forward. The free assessment takes about five minutes.

Book a Consultation Take the Assessment

References

1. Garber JR, et al. Clinical practice guidelines for hypothyroidism in adults. Endocr Pract. 2012;18(6):988–1028. doi:10.4158/EP12280.GL
2. Bianco AC, et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002;23(1):38–89. doi:10.1210/edrv.23.1.0455
3. Gereben B, et al. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev. 2008;29(7):898–938. doi:10.1210/er.2008-0019
4. Köhrle J. Selenium and the thyroid. Curr Opin Endocrinol Diabetes Obes. 2015;22(5):392–401. doi:10.1097/MED.0000000000000190
5. Betsy A, et al. Zinc deficiency associated with hypothyroidism: an overlooked cause of severe alopecia. Int J Trichology. 2013;5(1):40–42. doi:10.4103/0974-7753.114714
6. Walter KN, et al. Elevated thyroid stimulating hormone is associated with elevated cortisol in healthy young men and women. Thyroid Res. 2012;5(1):13. doi:10.1186/1756-6614-5-13
7. Fliers E, et al. Thyroid function in critically ill patients. Lancet Diabetes Endocrinol. 2015;3(10):816–825. doi:10.1016/S2213-8587(15)00225-9
8. Peeters RP, et al. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab. 2003;88(7):3202–3211. doi:10.1210/jc.2002-022013
9. Pagadala MR, et al. Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci. 2012;57(2):528–534. doi:10.1007/s10620-011-2006-2
10. Virili C, Centanni M. Does microbiota composition affect thyroid homeostasis? Endocrine. 2015;49(3):583–587. doi:10.1007/s12020-014-0509-2
11. Wartofsky L, Burman KD. Alterations in thyroid function in patients with systemic illness: the “euthyroid sick syndrome”. Endocr Rev. 1982;3(2):164–217. doi:10.1210/edrv-3-2-164
12. Gartner R, et al. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J Clin Endocrinol Metab. 2002;87(4):1687–1691. doi:10.1210/jcem.87.4.8421
13. Toulis KA, et al. Selenium supplementation in the treatment of Hashimoto’s thyroiditis: a systematic review and a meta-analysis. Thyroid. 2010;20(10):1163–1173. doi:10.1089/thy.2009.0351
14. Ventura M, et al. Selenium and thyroid disease: from pathophysiology to treatment. Int J Endocrinol. 2017;2017:1297658. doi:10.1155/2017/1297658
15. Panicker V, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab. 2009;94(5):1623–1629. doi:10.1210/jc.2008-1301
16. Mancini A, et al. Thyroid hormones, oxidative stress, and inflammation. Mediators Inflamm. 2016;2016:6757154. doi:10.1155/2016/6757154
17. Knezevic J, et al. Thyroid–gut axis: how does the microbiota influence thyroid function? Nutrients. 2020;12(6):1769. doi:10.3390/nu12061769
18. Mehran L, et al. Thyroid hormone profile and its association with metabolic and inflammatory parameters in obesity. Endocr Res. 2017;42(2):112–120. doi:10.1080/07435800.2016.1262869